Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than their home to ensure timely access to the medications at discharge, the Centers for Medicare & Medicaid Services announced last week in updated guidance. “In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge,” the guidance states. “In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary’s immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient’s home address.” AHA advocated for the policy change.

Related News Articles

Headline
The Medicare Payment Advisory Commission this week recommended that Congress provide a 2 percent market-basket update for the hospital inpatient an
Headline
The Center for Medicare and Medicaid Innovation today announced a new
Headline
Commenting today on the Medicare Payment Advisory Commission’s draft recommendations for 2020, AHA said it supports the recommendation to provide current law…
Headline
The U.S. Supreme Court yesterday heard oral arguments in an appeal of a D.C. Circuit Court decision that the Department of Health and Human Services violated…
Headline
The Centers for Medicare…
Blog
AHA outside counsel Sean Marotta shares insight from yesterday’s oral arguments before the Supreme Court in a case about when the Department of Health and…